Business Context and Reporting Period
Rhythm Pharmaceuticals, Inc. (RYTM) filed a Form 8-K on January 9, 2026, to disclose preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The filing also includes updates on clinical trial milestones and regulatory expectations for its lead product, IMCIVREE (setmelanotide), and other pipeline candidates.
Key Financial Metrics
- Q4 2025 Net Product Revenues: Approximately $57 million.
- Full Year 2025 Net Product Revenues: Approximately $194 million.
- Full Year 2024 Net Product Revenues: $130 million.
- Geographic Mix (Q4 2025): U.S. sales contributed approximately 68% of revenues.
- Geographic Mix (Full Year 2025): U.S. sales contributed approximately 69% of revenues.
- Other Metrics: The filing text does not provide clear values for profit, cash flow, margins, debt, or liquidity.
Material Changes
- Sequential Growth: Q4 2025 revenues increased 11% compared to Q3 2025.
- Year-Over-Year Growth: Full-year 2025 revenues increased approximately 50% compared to full-year 2024.
Outlook, Milestones, and Risks
Regulatory and Clinical Milestones
- Acquired Hypothalamic Obesity (HO): FDA PDUFA goal date for U.S. launch is March 20, 2026. Topline data for the Japanese Phase 3 cohort expected in Q1 2026.
- Congenital HO: Enrollment in the Phase 3 substudy expected to complete in H1 2026.
- MC4R Pathway Diseases: Topline data from the Phase 3 EMANATE trial expected in Q1 2026.
- Prader-Willi Syndrome (PWS): Six-month results from the Phase 2 trial (18 patients) anticipated in H1 2026.
- Bivamelagon: Pivotal Phase 3 trial in acquired HO expected to initiate in 2026 pending regulatory feedback.
- RM-718: Enrollment in Phase 1, Part C trial expected to complete in Q1 2026.
Risks and Contingencies
- Unaudited Data: Financial results are preliminary estimates; actual results may vary upon completion of financial closing and audit procedures.
- Forward-Looking Statements: Risks include potential deviations in financial results, clinical trial enrollment and outcomes, regulatory approval timing, pricing regulations, and competition.
Investor Verification Checklist
- Verify the final audited financial statements for Q4 and FY 2025 against these preliminary estimates.
- Monitor the FDA decision on the U.S. launch of IMCIVREE for acquired HO by the March 20, 2026 PDUFA date.
- Review the topline data releases for the Japanese HO cohort and the EMANATE trial in Q1 2026.
- Assess the impact of the 50% revenue growth on the company's path to profitability and cash burn rate.